To the full analysis
Buyback calculator for BeOne Medicines
BeOne Medicines stock: key metrics
ONCBeOne Medicines had an operating margin of 8.4% and a return on invested capital (ROIC) of 17.1% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2013 | −20.8% | −49.0% | −67.2% |
| 2014 | −67.7% | −120.9% | −140.2% |
| 2015 | −560.7% | −643.7% | −647.7% |
| 2016 | −9,062.0% | −10,940.2% | −11,141.8% |
| 2017 | −14.9% | −41.3% | −39.1% |
| 2018 | −257.0% | −356.1% | −339.9% |
| 2019 | 83.4% | −224.2% | −221.5% |
| 2020 | 77.1% | −536.7% | −526.1% |
| 2021 | 86.0% | −122.3% | −123.9% |
| 2022 | 79.8% | −126.4% | −141.5% |
| 2023 | 84.5% | −49.1% | −35.9% |
| 2024 | 84.4% | −14.9% | −16.9% |
| 2025 | 87.5% | 8.4% | 5.4% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2013 | 19.4% | no data | −63.5% |
| 2014 | −70.9% | −61.3% | −34.1% |
| 2015 | 56.1% | −65.6% | −48.9% |
| 2016 | −33.8% | −39.6% | −29.4% |
| 2017 | −13.6% | −12.2% | −8.9% |
| 2018 | −38.4% | −38.2% | −29.9% |
| 2019 | −98.6% | −45.8% | −58.8% |
| 2020 | −42.0% | −42.5% | −29.0% |
| 2021 | −23.8% | −18.6% | −17.1% |
| 2022 | −45.7% | −22.4% | −31.4% |
| 2023 | −24.9% | −19.2% | −15.2% |
| 2024 | −19.4% | −29.1% | −10.9% |
| 2025 | 6.6% | 17.1% | 3.5% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong since 8 Nov 2026, previously Neutral
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.